Sanara MedTech Inc. reported significant financial performance improvements in its latest 10-Q filing for the quarter ending June 30, 2025. The company achieved net revenue of $25.8 million for the three months ended June 30, 2025, marking a 28% increase from $20.2 million in the same period last year. For the six months ended June 30, 2025, net revenue reached $49.3 million, up 27% from $38.7 million in the prior year. The growth was primarily driven by increased sales of soft tissue repair products, including CellerateRX Surgical and BIASURGE, as well as certain bone fusion products.
Despite the revenue growth, Sanara MedTech reported a net loss of $2.0 million for the second quarter of 2025, an improvement from a net loss of $3.5 million in the same quarter of 2024. The company’s total net loss for the six months ended June 30, 2025, was $5.5 million, slightly higher than the $5.3 million loss reported for the same period in 2024. The increase in losses was attributed to higher costs associated with the buildout of the Tissue Health Plus (THP) platform and increased interest expenses related to the CRG Term Loan.
Operationally, Sanara MedTech has made strategic advancements, including the acquisition of CarePICS, LLC, which was completed on April 1, 2025, for $2.0 million in cash and the assumption of $1.65 million in existing debt. This acquisition is expected to enhance the company’s capabilities in value-based wound care services. Additionally, the company launched its first pilot program under the THP segment during the second quarter of 2025, although it has not yet generated revenue.
The company’s total assets increased to $98.8 million as of June 30, 2025, compared to $88.1 million at the end of 2024. This growth was supported by a rise in cash reserves to $17.0 million, up from $15.9 million at the end of the previous fiscal year. Sanara MedTech's employee headcount also increased, reflecting its ongoing expansion efforts. The company continues to focus on enhancing its market presence and product offerings, particularly in the surgical and wound care markets, while navigating the challenges of increased operational costs and interest expenses.
Looking ahead, Sanara MedTech anticipates continued investment in its THP strategy, projecting cash investments between $5.5 million and $6.5 million during the second half of 2025. The company believes that its current cash reserves, combined with expected cash flows from operations and available borrowing under the CRG Term Loan, will be sufficient to support its growth initiatives and operational needs for at least the next 12 months.
About Sanara MedTech Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.